Oncolytics Biotech Inc T.ONC

For Notable. From "Science" 9Dec 21

[askretka]

https://www.science.org/doi/10.1126/science.abk3436 Its the abstract only from well known Oncology virus researcher Alan Melcher. It's the Abstract only but I found this part very interesting. ------------------------------------------ (1). This view has now been largely replaced by a model in which infection of the tumor by the virus makes it more visible to the immune system for recognition and attack. Tumor cell killing by the virus and/or immune effector cells EFFECTIVELY GENERATE AN IN SITU VACCINE, with tumor antigens released into a microenvironment modified by viral infection to reverse tumor-induced immune suppression. -------------------------------------------------------- Cheers!!!

[Noteable]

The "new" model of oncoloytic virus therapy is one that ONCY has been demonstrating in the application of pelareorep and its ability to stimulate the innate and adaptive immune system with the effect of overcoming an otherwise immunosuppressive tumor microenvironment (TME) in advance of the addition of checkpoint inhibitor therapy  Independent studies have recently shown that

[Noteable]

February 14, 2022 -   Harnessing the Immune System to Treat Cancers - [Cancer Research] Combining virotherapy with checkpoint inhibitors "The field is now looking more closely at combining therapeutics, for example administering immunotherapy and virotherapy in different combinations and orders. Using the strengths of each to help each other." https://www.technologynetworks

[askretka]

Thanks for the Feb 14 link.   https://www.technologynetworks.com/cancer-research/articles/harnessing-the-immune-system-to-treat-cancer-358080 ----------------- "But the downside to this approach is that “for about 80% of cancers, you can't find them, you don't know where they are, they're not amenable to a needle. Therefore, intratumoral delivery doesn't work for

[askretka]

Thanks Notable. Things seem a bit too for me on the CAR-T front, but after the recent news on CAR-T 10 year survival rate and Novartis possibly with an in Vivo CAR-T in the works, timing for a CAR-T/Pela deal couldn't be better in my opinion. Cheers!!!!